Zydus Lifesciences Ltd.
BSE: 532321 | NSE: ZYDUSLIFE
Mid Cap | Pharmaceuticals & Drugs
928.85
-7.50 (-0.80%) Zydus Lifesciences informs about press release
Date: 07-06-2022Zydus Lifesciences has informed that it enclosed a copy of press release dated June 7, 2022 titled ‘Zydus Lifesciences receives final approval from USFDA for Adapalene and Benzoyl Peroxide Topical Gel’.
The above information is a part of company’s filings submitted to BSE.